Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.
Launched by BALL STATE UNIVERSITY · Jun 24, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether eating fresh mango instead of regular table sugar in breakfast meals can help keep blood sugar and insulin levels steadier after eating. Since big spikes in blood sugar and insulin after meals can increase the risk of diabetes and heart problems, the researchers want to see if mango—which naturally contains fiber and other healthy plant substances—might lead to better blood sugar and heart-related responses compared to regular sugar. They will compare how meals sweetened with fresh mango versus table sugar affect blood sugar, insulin, and blood vessel health in healthy adults.
To take part, you need to be between 18 and 45 years old, have a body weight in a healthy or slightly overweight range, and be generally healthy without diabetes, heart disease, or chronic inflammatory conditions. Women who are pregnant or past menopause cannot join. Participants should not regularly use certain medications like anti-inflammatory or cholesterol-lowering drugs and must be able to eat mango, wheat, gluten, and milk without problems. During the study, you can expect to eat different breakfast meals and have your blood sugar, insulin, and blood vessel responses measured after eating. You will also need to lie quietly in a darkened room for a short time. This study is currently recruiting volunteers who meet these criteria to better understand if fresh mango can be a healthier alternative to sugar in everyday meals.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 - 45 years.
- • Body mass index between 18.5-35.0 kg/m2
- • Not pregnant (females only)
- • Not postmenopausal (females only).
- • Not been diagnosed with cardiovascular disease.
- • Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
- • Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
- • Does not regularly take anti-inflammatory drugs (more than 2x week).
- • Does not use glucose-lowering drugs (e.g., metformin)
- • Does not use lipid-lowering drugs (e.g., statins)
- • Does not use tobacco products or any illicit drugs.
- • Does not have a pacemaker.
- • Can consume mango, wheat, gluten, and milk.
- • Can stay in a supine position in the dark for at least ten minutes.
- Exclusion Criteria:
- • Not between the ages of 18-45
- • Body mass index \< 18.5 kg/m2 or \>35.0 kg/m2
- • Pregnant (females only)
- • Postmenopausal status (females only).
- • Been diagnosed with cardiovascular disease.
- • Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)
- • Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).
- • Regularly take anti-inflammatory drugs (more than 2x week).
- • Uses glucose-lowering drugs (e.g., metformin)
- • Uses lipid-lowering drugs (e.g., statins)
- • Uses tobacco products or any illicit drugs.
- • Have a pacemaker.
- • Allergic to mango, wheat, gluten, and/or milk.
- • Unable to lay in supine position in the dark for at least ten minutes.
About Ball State University
Ball State University is a distinguished academic institution committed to advancing research and innovation in various fields, including clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its comprehensive resources and expertise to conduct rigorous research that enhances healthcare outcomes. Ball State University fosters an environment of academic excellence, ensuring that all clinical trials adhere to the highest ethical standards while contributing valuable insights to the medical community. Through its dedicated faculty and state-of-the-art facilities, the university aims to drive forward scientific knowledge and improve patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Muncie, Indiana, United States
Patients applied
Trial Officials
Bryant Keirns, PhD
Principal Investigator
Ball State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported